{'fraction_non_alphanumeric': 0.03195739014647137, 'fraction_numerical': 0.017310252996005325, 'mean_word_length': 4.740458015267175, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Timely Administration of Birth Dose Hepatitis B Virus Vaccine May Break the Chain of Perinatal Transmission

This is a multicenter, double-blind, placebo-controlled clinical trial conducted in Thailand. A total of 331 HBeAg positive pregnant women with hepatitis B infection were randomly assigned to receive either TDF (n = 168) or placebo (n = 163) from 28 weeks of gestation to two months postpartum. Subjects with HIV or HCV coinfection were excluded. Standardized doses of HBIG (Grifols) and HBV vaccine (10 μg) at birth and one, two, four and six months were administered to the infants. The primary study endpoint was the HBV-positive status in the infants at six months after birth. This article is protected by copyright. All rights reserved.